PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours
PATRIOT:一项 I 期研究,旨在评估一种特定的共济失调毛细血管扩张症和 Rad3 相关 (ATR) 抑制剂 (AZD6738) 作为单药以及与姑息性放射疗法联合用于实体瘤患者的耐受性、安全性和生物学效应。
期刊:Clinical and Translational Radiation Oncology
影响因子:2.7
doi:10.1016/j.ctro.2018.06.001
Dillon, M T; Boylan, Z; Smith, D; Guevara, J; Mohammed, K; Peckitt, C; Saunders, M; Banerji, U; Clack, G; Smith, S A; Spicer, J F; Forster, M D; Harrington, K J